期刊
AGE AND AGEING
卷 45, 期 2, 页码 262-267出版社
OXFORD UNIV PRESS
DOI: 10.1093/ageing/afv200
关键词
polypharmacy; geriatric pharmacotherapy; clinical trial; FORTA score; activities of daily living; older people
资金
- DFG-German Research Foundation [WE 1184/15-1, FR2997/2-1]
Methods: patients (a parts per thousand yen65 years, a parts per thousand yen3 drugs or a parts per thousand yen60 years, a parts per thousand yen6 drugs) with three relevant diseases and hospitalisation for a parts per thousand yen5 days were randomised. In the intervention, but not the control group, a FORTA team instructed ward physicians on FORTA. FORTA is the first positive/negative listing approach labelling medications used to treat chronic illnesses in older patients from A (indispensable), B (beneficial), C (questionable) to D (avoid). The primary end point was the FORTA score: sum of medication errors classified as over-, under- and mistreatment. Consecutive patients were randomised to the intervention and control ward; outcome assessment was blinded. Results: four hundred and nine patients (age 81.5 years, 64% female, hospitalisation 17.4 days) were included. The primary end point was significantly (P < 0.0001) more reduced in the intervention versus control groups (2.7 +/- 2.25 versus 1 +/- 1.8, mean +/- SD, intergroup comparison of admission/discharge differences). Over- and under-treatment scores and use of A (increase) and D (decrease) drugs were significantly improved (P < 0.01). The total number of adverse drug reactions (ADRs) was significantly reduced by FORTA (P < 0.05, number needed to treat is 5). Activities of daily living and renal failure improved significantly (P < 0.05). Blood pressure remained constant in the intervention, but decreased significantly in the control group. Conclusion: applying FORTA to hospitalised geriatric patients leads to improvement of medication quality and may improve secondary clinical end points (e.g. ADRs). The concept is amenable to successful communication and implementation. Registration (DRKS-ID): DRKS00000531. Funding: DFG-German Research Foundation (WE 1184/15-1).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据